DOCSLIB.ORG

Informing Treatment Strategies Through a Comprehensive Approach

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Informing Treatment Strategies Through a Comprehensive Approach Informing Treatment Strategies Through a Comprehensive Approach Enter Informing Treatment Strategies Through a Comprehensive Approach INTRO FOUNDATION MEDICINE Precision medicine Tests Recent therapies Latest data - FoundationOne®CDx Latest data - FoundationOne®Liquid CDx WHY COMPREHENSIVE Latest data - FoundationOne®Heme GENOMIC PROFILING? Support services Comprehensive testing Implications of comprehensive genomic profiling Integrating comprehensive genomic profiling Want to know more? EARLIER USE Look out for information bubbles like the one shown here: Earlier use i These represent clickable objects that offer more information. MENU WHY COMPREHENSIVE INTRO EARLIER USE FOUNDATION MEDICINE GENOMIC PROFILING Precision medicine Introduction Recent therapies MENU - INTRODUCTION WHY COMPREHENSIVE INTRO EARLIER USE FOUNDATION MEDICINE GENOMIC PROFILING The power of precision medicine is only growing stronger Recent therapies Today In development From 2013 to 20201 55+ FDA-approved >4200 2 90+ active oncology trials in the US indications >1/3 of active oncology clinical trials in the Covering US use genomics for patient selection3 New FDA-approved 25+ agents1 cancer types 91% of oncology drugs in late-stage pharma pipelines are targeted therapies3 Continual targeted therapy approvals & developing clinical trials expand the reach of precision medicine INTRO Page 1 / 2 i References WHY COMPREHENSIVE INTRO EARLIER USE FOUNDATION MEDICINE GENOMIC PROFILING The power of precision medicine is only growing stronger Recent therapies References 1. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet#what-types-of-targeted-therapies-are-available Accessed April 2020 2. ClinicalTrials.gov. Search for Active, not recruiting Studies, Oncology, United States on 8/28/2019. Retrieved from https://clinicaltrials.gov/ct2/results?cond=Oncology&cntry=US&Search=Apply&recrs=d&age_v=&gndr=&type=&rslt= 3. IQVIA Institute for Human Data Science. (May 2019). Global Oncology Trends 2019; Therapeutics, Clinical Development and Health System Implications. Retrieved from https://www.iqvia.com/institute/reports/global-oncology-trends-2019. INTRO Page 2 / 2 i References WHY COMPREHENSIVE INTRO EARLIER USE FOUNDATION MEDICINE GENOMIC PROFILING A comprehensive approach to testing keeps you up to date Why comprehensive with the most recent treatment options for your patients genomic profiling Drugs Indicators Indicators Drugs entrectinib larotrectinib selpercatinib capmatinib alpelisib olaparib erdafitinib Recent approvals capmatinib, pemigatinib, selpercatinib, olaparib and label expansions: pemigatinib INTRO Page 2 / 2 WHY COMPREHENSIVE INTRO EARLIER USE FOUNDATION MEDICINE GENOMIC PROFILING Why Comprehensive Comprehensive testing Implications of comprehensive genomic profiling Genomic Profiling? Integrating comprehensive genomic profiling MENU - WHY COMPREHENSIVE GENOMIC PROFILING WHY COMPREHENSIVE INTRO EARLIER USE FOUNDATION MEDICINE GENOMIC PROFILING Implications of comprehensive More insights and fewer missed opportunities from a single test genomic profiling Comprehensive i Single marker i Hotspot i Genomic Profiling Oncomine Dx Target Test NeoGenomics ALK FISH Test FoundationOne®CDx (Thermo Fisher) or FoundationOne®Liquid CDx EGFR EGFR i KRAS KRAS BRAF BRAF ALK ALK ALK ERBB2 ERBB2 MET MET i ROS1 ROS1 NTRK1 i NTRK2 NTRK3 RET RET STK11 Legend: Substitutions InDels Rearrangements CNAs Not Detected Biomarkers shown in table above are examples of relevant and emerging biomarkers in non-small cell lung cancer (NSCLC). NeoGenomics ALK FISH Test and Oncomine Dx are examples of single biomarker and hotspot tests. WHY COMPREHENSIVE Page 1 / 3 i GENOMIC PROFILING References WHY COMPREHENSIVE INTRO EARLIER USE FOUNDATION MEDICINE GENOMIC PROFILING Implications of comprehensive More insights and fewer missed opportunities from a single test genomic profiling Comprehensive i Single marker i Hotspot i Genomic Profiling Oncomine Dx Target Test NeoGenomics ALK FISH Test FoundationOne®CDx (Thermo Fisher) or FoundationOne®Liquid CDx EGFR exon 19 deletion EGFR EGFR i See Sample report KRAS KRAS BRAF BRAF ALK ALK ALK ERBB2 ERBB2 MET MET i ROS1 ROS1 NTRK1 i NTRK2 NTRK3 RET RET STK11 Legend: Substitutions InDels Rearrangements CNAs Not Detected Biomarkers shown in table above are examples of relevant and emerging biomarkers in non-small cell lung cancer (NSCLC). NeoGenomics ALK FISH Test and Oncomine Dx are examples of single biomarker and hotspot tests. WHY COMPREHENSIVE Page 1 / 3 i GENOMIC PROFILING References WHY COMPREHENSIVE INTRO EARLIER USE FOUNDATION MEDICINE GENOMIC PROFILING Implications of comprehensive More insights and fewer missed opportunities from a single test genomic profiling Comprehensive i Single marker i Hotspot i Genomic Profiling Oncomine Dx Target Test NeoGenomics ALK FISH Test FoundationOne®CDx (Thermo Fisher) or FoundationOne®Liquid CDx EGFR EGFR i KRAS KRAS BRAF BRAF ALK ALK ALK ERBB2 ERBB2 MET amplification MET MET i See Sample report ROS1 ROS1 NTRK1 i NTRK2 NTRK3 RET RET STK11 Legend: Substitutions InDels Rearrangements CNAs Not Detected Biomarkers shown in table above are examples of relevant and emerging biomarkers in non-small cell lung cancer (NSCLC). NeoGenomics ALK FISH Test and Oncomine Dx are examples of single biomarker and hotspot tests. WHY COMPREHENSIVE Page 1 / 3 i GENOMIC PROFILING References WHY COMPREHENSIVE INTRO EARLIER USE FOUNDATION MEDICINE GENOMIC PROFILING Implications of comprehensive More insights and fewer missed opportunities from a single test genomic profiling Comprehensive i Single marker i Hotspot i Genomic Profiling Oncomine Dx Target Test NeoGenomics ALK FISH Test FoundationOne®CDx (Thermo Fisher) or FoundationOne®Liquid CDx EGFR EGFR i KRAS KRAS BRAF BRAF ALK ALK ALK ERBB2 ERBB2 MET MET i ROS1 ROS1 NTRK1 BGLAP fusion NTRK1 i See Sample report NTRK2 NTRK3 RET RET STK11 Legend: Substitutions InDels Rearrangements CNAs Not Detected Biomarkers shown in table above are examples of relevant and emerging biomarkers in non-small cell lung cancer (NSCLC). NeoGenomics ALK FISH Test and Oncomine Dx are examples of single biomarker and hotspot tests. WHY COMPREHENSIVE Page 1 / 3 i GENOMIC PROFILING References WHY COMPREHENSIVE INTRO EARLIER USE FOUNDATION MEDICINE GENOMIC PROFILING Implications of comprehensive More insights and fewer missed opportunities from a single test genomic profiling Comprehensive i Single marker i Hotspot i Genomic Profiling Oncomine Dx Target Test NeoGenomics ALK FISH Test FoundationOne®CDx (Thermo Fisher) or FoundationOne®Liquid CDx EGFR EGFR i KRAS KRAS BRAF BRAF ALK ALK ALK ERBB2 ERBB2 MET MET i ROS1 ROS1 NTRK1 i NTRK2 NTRK3 RET RET STK11 Single biomarker testing identifies alterations confined to a single gene, resulting in potentially missing clinically relevant mutations in additional genes Legend: Substitutions InDels Rearrangements CNAs Not Detected Biomarkers shown in table above are examples of relevant and emerging biomarkers in non-small cell lung cancer (NSCLC). NeoGenomics ALK FISH Test and Oncomine Dx are examples of single biomarker and hotspot tests. WHY COMPREHENSIVE Page 1 / 3 i GENOMIC PROFILING References WHY COMPREHENSIVE INTRO EARLIER USE FOUNDATION MEDICINE GENOMIC PROFILING Implications of comprehensive More insights and fewer missed opportunities from a single test genomic profiling Comprehensive i Single marker i Hotspot i Genomic Profiling Oncomine Dx Target Test NeoGenomics ALK FISH Test FoundationOne®CDx (Thermo Fisher) or FoundationOne®Liquid CDx EGFR EGFR i KRAS KRAS BRAF BRAF ALK ALK ALK ERBB2 ERBB2 MET MET i ROS1 ROS1 NTRK1 i NTRK2 NTRK3 RET RET STK11 Gene hotspot testing may test multiple genes at a time, but is confined to hotspot regions within those genes, resulting in potentially missing other clinically relevant classes of alterations Legend: Substitutions InDels Rearrangements CNAs Not Detected Biomarkers shown in table above are examples of relevant and emerging biomarkers in non-small cell lung cancer (NSCLC). NeoGenomics ALK FISH Test and Oncomine Dx are examples of single biomarker and hotspot tests. WHY COMPREHENSIVE Page 1 / 3 i GENOMIC PROFILING References WHY COMPREHENSIVE INTRO EARLIER USE FOUNDATION MEDICINE GENOMIC PROFILING Implications of comprehensive More insights and fewer missed opportunities from a single test genomic profiling Comprehensive i Single marker i Hotspot i Genomic Profiling Oncomine Dx Target Test NeoGenomics ALK FISH Test FoundationOne®CDx (Thermo Fisher) or FoundationOne®Liquid CDx EGFR EGFR i KRAS KRAS BRAF BRAF ALK ALK ALK ERBB2 ERBB2 MET MET i ROS1 ROS1 NTRK1 i NTRK2 NTRK3 RET RET STK11 Comprehensive genomic profiling detects the 4 main classes of genomic alterations across a broader panel of genes Legend: Substitutions InDels Rearrangements CNAs Not Detected Biomarkers shown in table above are examples of relevant and emerging biomarkers in non-small cell lung cancer (NSCLC). NeoGenomics ALK FISH Test and Oncomine Dx are examples of single biomarker and hotspot tests. WHY COMPREHENSIVE Page 1 / 3 i GENOMIC PROFILING References WHY COMPREHENSIVE INTRO EARLIER USE FOUNDATION MEDICINE GENOMIC PROFILING Implications of comprehensive More insights and fewer missed opportunities from a single test genomic profiling References, Indications and Precautions 1. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019C.pdf 2. https://www.clinical-lung-cancer.com/article/S1525-7304(18)30204-3/fulltext#tblS1 EGFR rbb2-amplification/ 1. https://www.sciencedirect.com/science/article/pii/S0093
Load more

Recommended publications
  • Cogent Biosciences Announces Creation of Cogent Research Team
    Cogent Biosciences Announces Creation of Cogent Research Team April 6, 2021 Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million supports company goals into 2024, including three CGT9486 clinical trials on-track to start this year, beginning with ASM in 1H21 BOULDER, Colo. and CAMBRIDGE, Mass., April 6, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the formation of the Cogent Research Team led by newly appointed Chief Scientific Officer, John Robinson, PhD. "Today marks an important step forward for Cogent Biosciences as we announce the formation of the Cogent Research Team with a focus on discovering and developing new small molecule therapies for patients fighting rare, genetically driven diseases," said Andrew Robbins, President and Chief Executive Officer of Cogent Biosciences. "I am thrilled to welcome John onboard as Cogent Biosciences' Chief Scientific Officer. John's expertise and seasoned leadership make him ideally suited to lead this new team of world class scientists. Given the team's impressive experience and accomplishments, we are excited for Cogent Biosciences' future and the opportunity to expand our pipeline and deliver novel precision therapies for patients." With an exceptional track record of innovation, the Cogent Research Team will focus on pioneering best-in-class, small molecule therapeutics to both improve upon existing drugs with clear limitations, as well as create new breakthroughs for diseases where others have been unable to find solutions.
    [Show full text]
  • Tabrecta (Capmatinib)
    Tabrecta (capmatinib) NEW PRODUCT SLIDESHOW Introduction . Brand name: Tabrecta . Generic name: Capmatinib . Pharmacologic class: Kinase inhibitor . Strength and Formulation: 150mg, 200mg; tablets . Manufacturer: Novartis . How supplied: Tabs—56 . Legal Classification: Rx Tabrecta Indication Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA- approved test . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) Dosage and Administration Confirm presence of a mutation that leads to MET exon 14 skipping in tumor specimens Swallow whole 400mg twice daily Recommended dose reductions for adverse reactions: . First: 300mg twice daily . Second: 200mg twice daily . Permanently discontinue in patients unable to tolerate 200mg twice daily Dosage Modifications for Adverse Reactions Interstitial lung disease/pneumonitis . Any grade: permanently discontinue Increased ALT and/or AST without increased total bilirubin . Grade 3: withhold until recovery to baseline ALT/AST; if recovery to baseline within 7 days, then resume at same dose, otherwise resume at a reduced dose . Grade 4: permanently discontinue Increased ALT and/or AST with increased total bilirubin in the absence of cholestasis or hemolysis . ALT and/or AST >3xULN with total bilirubin >2xULN: permanently discontinue Dosage Modifications for Adverse Reactions Increased total bilirubin without concurrent increased ALT and/or AST . Grade 2: withhold until recovery to baseline bilirubin; if recovered to baseline within 7 days, then resume at same dose, otherwise resume at reduced dose . Grade 3: withhold until recovery to baseline bilirubin; if recovered to baseline within 7 days, then resume at reduced dose, otherwise permanently discontinue .
    [Show full text]
  • Incyte Corporation
    Building Value through Innovative Medicines 2019 First Quarter Financial and Corporate Update April 30, 2019 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: expectations regarding ruxolitinib, ruxolitinib cream, itacitinib, pemigatinib, parsaclisib and INCMGA0012 trial results and timing of the receipt and presentation of those results; the expected timing of the NDA submissions for pemigatinib and capmatinib; our belief that certain of our projects, such as the acceleration of vitiligo development and opportunities with pemigatinib and itacitinib, warrant increased near-term funding; expectations regarding planned regulatory updates, planned pivotal clinical updates and planned clinical trial initiations; expectations by our collaborative partners regarding timing of NDA submission for capmatinib and announcement of baricitinib trial results; our plans and expectations for development of, and clinical trials involving, our other product candidates, including the potential timing for regulatory submissions; our plans for immediate launch of ruxolitinib for steroid-refractory acute GVHD should the FDA approve our sNDA; our updated 2019 GAAP and non-GAAP guidance; our expectations regarding baricitinib royalties; and our expected 2019 newsflow events. These forward-looking statements are based on our current expectations and are subject to risks
    [Show full text]
  • Systematic Review: Targeting HER2 in Bladder Cancer
    Bladder Cancer 5 (2019) 1–12 1 DOI 10.3233/BLC-180196 IOS Press Systematic Review Systematic Review: Targeting HER2 in Bladder Cancer Vadim S. Koshkina, Peter O’Donnellb,EvanY.Yuc and Petros Grivasd,∗ aDepartment of Medicine, Division of Hematology and Oncology, University of California San Francisco, CA, USA bDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA cDepartment of Medicine, Division of Oncology, Clinical Research Director, Fred Hutchinson Cancer Research Center, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA dDepartment of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA Received 23 August 2018 Accepted 22 November 2018 Abstract. Background: HER2 (ErbB2) is a receptor of the Human Epidermal Growth Factor Receptor (HER) family whose role in oncogenesis of numerous malignancies is well described. Drugs targeting HER2 are currently approved in breast and gastroesophageal cancers while pan-HER targeting agents are being evaluated in multiple malignancies. HER2 genomic alterations are commonly described in urothelial cancer and multiple trials have assessed the efficacy of anti-HER2 agents in both muscle-invasive and metastatic urothelial carcinoma. Objective: To review prospective clinical trials of therapeutic agents with HER2–targeting activity in patients with bladder cancer. Methods: A systematic search of PubMed, ASCO abstracts and Clinicaltrials.gov was performed to identify studies of HER2–targeting agents in bladder cancer. Reported results from prospective trials were reviewed and summarized. Results: Eleven prospective clinical trials with reported results were identified that investigated activity of trastuzumab, lapatinib, neratinib, afatinib, or autologous cellular immunotherapy, (DN24–02), in various bladder cancer treatment settings.
    [Show full text]
  • Leukemia Insights June 2021
    JUNE 2021 In this month’s Leukemia Insights newsletter, written by Prithviraj Bose, M.D. and Srdan Verstovsek, M.D., Ph.D., and sponsored in part by the Charif Souki Cancer Research ABOUT MyMDAnderson Fund, we discuss our novel therapeutic approaches for the rare hematologic malignancies, systemic mastocytosis and myeloid/lymphoid neoplasms with myMDAnderson is a secure, eosinophilia. Learn more about our Leukemia program. personalized web site helping community physicians expedite patient referrals, as well as improve continuity Spotlight on rare, atypical, myeloid of care through information access and streamlined communications. neoplasms: systemic mastocytosis and Physicians who have referred patients myeloid/lymphoid neoplasms with to MD Anderson or plan to do so, can utilize the HIPAA compliant features eosinophilia and FGFR1 rearrangements of myMDAnderson to: • Refer a patient • View your patient's appointments Systemic Mastocytosis Access patient reports • Send and receive secure Systemic mastocytosis (SM) is a rare myeloid neoplasm messages driven in approximately 95% of cases by an activating mutation in c-KIT, usually D816V. SM is characterized as indolent, smoldering or advanced, based on the presence JOIN THE COVERSATION and number of so-called B- and C-findings. The latter Connect with us. signify organ damage and are a hallmark of advanced SM (AdvSM). AdvSM, in turn, is typically sub-classified as aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN, the most common subtype) and mast cell leukemia (MCL). Patients with indolent SM (ISM) and smoldering SM (SSM) enjoy much better survival than JOIN OUR MAILING LIST those with AdvSM, although symptoms in all three subtypes can be severe and debilitating.
    [Show full text]
  • Incyte Announces the European Commission Approval of Pemazyre
    3/29/2021 Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement - Pemazyre is the rst targeted therapy approved in the EU for this indication WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Pemazyre® (pemigatinib) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a broblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. The decision follows the positive opinion received from the European Medicines Agency’s Committee for Medicinal Products for Human Use in January 2021 recommending the conditional marketing authorization of Pemazyre. “Pemazyre’s approval is a crucial milestone for patients with FGFR2 positive cholangiocarcinoma. It is the rst new treatment option to be made available to these patients in the EU in over a decade and has demonstrated a high rate of durable responses in a setting where historically there has been no eective standard of care,” said Hervé Hoppenot, Chief Executive Ocer, Incyte. “We now look forward to working with individual countries in Europe to ensure eligible patients can access this new treatment as soon as possible.” The EC decision is based on data from the FIGHT-202 study evaluating the safety and ecacy of Pemazyre in adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with documented FGF/FGFR status. Interim results from FIGHT-202 demonstrated that in patients harboring FGFR2 fusions or rearrangements (Cohort A [108 patients]), Pemazyre monotherapy resulted in an overall response rate (ORR) of 37 percent (primary endpoint) and a median duration of response (DOR) of 8 months (secondary endpoint) based on an independent central radiographic review.
    [Show full text]
  • Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer
    Bladder Cancer 5 (2019) 87–102 87 DOI 10.3233/BLC-180205 IOS Press Review Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer Tony Ibrahima, Marco Gizzib, Ratislav Bahledac and Yohann Loriota,d,∗ aD´epartement de M´edecine Oncologique, Gustave Roussy, Universit´e Paris-Sud, Universit´e Paris-Saclay, Villejuif, France bDepartment of Medical Oncology. Grand Hˆopital de Charleroi, Charleroi, Belgium cDrug Development Department (DITEP), Gustave Roussy, Villejuif France dInserm 981, Universit´e Paris-Sud, Universit´e Paris Saclay, Villejuif, France Received: 29 November 2018 Accepted: 4 March 2019 Abstract. The fibroblast growth factor receptor 3 (FGFR3) plays critical roles in driving oncogenesis of a subset of patients with urothelial carcinomas (UC). Growing evidence from preclinical studies suggests that FGFR3 inhibition can reduce proliferation and survival in vitro and in vivo models of FGFR3-altered UC. Early clinical trials investigating selective FGFR3 inhibitor have reported preliminary signs of antitumor activity in advanced UC patients with selected FGFR3 mutations or fusions. Currently, phase 3 trials with erdafitinib and rogaratinib are enrolling patients with known FGFR3 alterations. Future combinations with targeted therapies or immune checkpoint inhibitors may increase the efficacy of selective FGFR3 inhibitors. Herein, we discuss current clinical development of FGFR3 inhibitors as well as unsolved questions with regards to patient selection, management of toxicities and mechanisms of resistance to selective FGFR3 inhibitors. Keywords: Urothelial cancer, bladder cancer, fibroblast growth factor 3, tyrosine kinase INTRODUCTION the treated patients [1–11]. Innovative strategies aim- ing to improve metastatic UC treatment efficacy have Metastatic urothelial carcinoma (UC) is frequent learned from targeted therapies in solid tumors such and has a poor prognosis.
    [Show full text]
  • Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
    Published OnlineFirst November 20, 2020; DOI: 10.1158/2159-8290.CD-20-0766 RESEARCH ARTICLE Clinicogenomic Analysis of FGFR2- Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib Ian M. Silverman1, Antoine Hollebecque2, Luc Friboulet2, Sherry Owens1, Robert C. Newton1, Huiling Zhen3, Luis Féliz4, Camilla Zecchetto5, Davide Melisi5, and Timothy C. Burn1 Downloaded from cancerdiscovery.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Published OnlineFirst November 20, 2020; DOI: 10.1158/2159-8290.CD-20-0766 ABSTRACT Pemigatinib, a selective FGFR1–3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions/rearrangements, and has gained regulatory approval in the United States. Eligibility for FIGHT- 202 was assessed using genomic profiling; here, these data were utilized to characterize the genomic landscape of cholangiocarcinoma and to uncover unique molecular features of patients harboring FGFR2 rearrangements. The results highlight the high percentage of patients with cholangiocarcinoma harboring potentially actionable genomic alterations and the diversity in gene partners that rear- range with FGFR2. Clinicogenomic analysis of pemigatinib-treated patients identified mechanisms of primary and acquired resistance. Genomic subsets of patients with other potentially actionable FGF/ FGFR alterations were also identified. Our study provides a framework for molecularly guided clinical trials and underscores the importance of genomic profiling to enable a deeper understanding of the molecular basis for response and nonresponse to targeted therapy. SIGNIFICANCE: We utilized genomic profiling data from FIGHT-202 to gain insights into the genomic landscape of cholangiocarcinoma, to understand the molecular diversity of patients with FGFR2 fusions or rearrangements, and to interrogate the clinicogenomics of patients treated with pemi- gatinib.
    [Show full text]
  • New ADC Shrinks HER2-Positive Tumors
    Published OnlineFirst August 2, 2019; DOI: 10.1158/2159-8290.CD-NB2019-089 NEWS IN BRIEF he says, “I can’t cancer, and 17 had HER2-low HR- fathom that cost.” negative breast cancer. The remaining Cytoplasm –Elie Dolgin n 47 patients had gastric, urothelial, or endometrial tumors. Eye-related side effects were again New ADC prevalent: 71% of patients were Shrinks affected by problems such as conjunc- tivitis, keratitis, and dry eye. These Nuclear pore HER2- adverse effects have been seen with complex Positive other ADCs—although they haven’t Tumors been described with T-DM1—but the mechanism remains unclear, says A novel co-author Philippe Aftimos, MD, of Nucleus antibody–drug the Jules Bordet Institute and the Free conjugate (ADC) University of Brussels in Belgium. Tumor suppressor protein Selective inhibitor of triggers responses nuclear export inhibitor The ADC produced partial + eiF4E-bound mRNA in patients with Regulatory factor XPO1 responses in 33% of the patients with HER2-expressing HER2-positive metastatic breast breast cancer Selinexor is a selective inhibitor of nuclear export. By blocking XPO1, it cancer; 28% with HER2-low, HR- prevents molecular cargo from moving through the nuclear pore complex, and other solid positive metastatic breast cancer; and causing cell-cycle arrest, apoptosis, and other antitumor activity. (Courtesy tumors, a phase I 40% with HER2-low, HR-negative of Karyopharm Therapeutics; modified with permission.) clinical trial metastatic breast cancer. The median indicates (Lancet progression-free survival for these Oncol 2019;20:1124–35). The drug commonly experienced side effects three groups was 7.6 months, such as thrombocytopenia, hypona- could become a new treatment for 4.1 months, and 4.9 months, respec- tremia, anemia, and nausea.
    [Show full text]
  • First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations
    First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations Patients with stage IV non-small cell lung cancer Nonsquamous cell carcinoma and squamous cell carcinoma Activating EGFR mutation other Sensitizing (L858R/exon 19 MET exon 14 skipping than exon 20 insertion mutations, EGFR exon 20 mutation ALK rearrangement ROS1 rearrangement BRAF V600E mutation RET rearrangement NTRK rearrangement mutations KRAS alterations HER2 alterations NRG1 alterations deletion) EGFR mutation T790M, L858R or Ex19Del PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options Emerging target; no Emerging target; no Emerging target; no Platinum doublet † † † Osimertinib monotherapy S Afatinib monotherapy M M Alectinib S Entrectinib M Dabrafenib/trametinib M Capmatinib M Selpercatinib M Entrectinib M conclusions available conclusions available conclusions available chemotherapy ± bevacizumab Gefitinib with doublet Standard treatment based on Standard treatment based on Standard treatment based on M M M Brigatinib S Crizotinib M M Tepotinib M Pralsetinib* W Larotrectinib M chemotherapy non-driver mutation guideline non-driver mutation guideline non-driver mutation guideline If alectinib or brigatinib are not available If entrectinib or crizotinib are not available Standard treatment based on Standard treatment based on Standard treatment based on Dacomitinib monotherapy M Osimertinib W M M M Ceritinib S Ceritinib W non-driver mutation guideline non-driver mutation guideline non-driver mutation guideline Monotherapy with afatinib M Crizotinib S Lortlatinib W Standard treatment based on Erlotinib/ramucirumab M M non-driver mutation guideline Erlotinib/bevacizumab M Monotherapy with erlotinib M Strength of Recommendation Monotherapy with gefitinib M S Strong M Moderate W Weak Monotherapy with icotinib M Notes.
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • | TIME TRIALS February 2021 Provides You Access to a Network of Just-In-Time Biomarker-Driven Trials for Your Patients
    Your organization has enrolled in the TIME TrialTM Network, which | TIME TRIALS February 2021 provides you access to a network of just-in-time biomarker-driven trials for your patients. Studies currently enrolling in the TIME TrialTM Program: SOLID TUMOR SOLID TUMOR CONT. Elevation ELVAP-001-01 Ideaya IDE196-001 GNAQ/11 hotspot mutation (CRESTONE) Phase I/II At least 1 prior standard therapy; NRG1 fusion Phase II NCT03947385 No prior treatment with a PKC At least 1 prior standard therapy NCT04383210 IDE196 inhibitor Seribantumab Janssen CAN2002 (RAGNAR) FGFR 1-4 fusions & specified Phase II mutations BREAST NCT04083976 At least 1 prior standard therapy JNJ-42756493 (Erdafitinib) Excludes Bladder Cancer HER2-, ER+ & ESR1 mutations Sermonix SMX 18-001 (ELAINE I) Progression following AI in Phase II Turning Point TPX-0005-01 combination with a CDK 4/6 inhibitor; (TRIDENT) NCT03781063 NTRK 1-3 fusions No more than 1 prior systemic Phase II Lasofoxifene or Fulvestrant Allowed up to 2 prior TRK TKIs chemotherapy NCT03093116 TPX-0005 (Repotrectinib) Sermonix SMX 20-001 (ELAINE II) HER2-, ER+ & ESR1 mutations Phase II Progression following first or second- Blueprint BLU-667-101 (ARROW) RET fusion NCT04432454 line hormone therapy; No more than 1 Phase I/II At least 1 prior standard therapy; no Lasofoxifene & Abemaciclib prior systemic chemotherapy NCT03037385 prior treatment with a selective RET Pralsetinib (BLU-667) inhibitor ; Excludes MTC and NSCLC Ayala AL-TNBC-01 (TENACITY) Notch Activation Phase II No more than three lines of systemic Merus
    [Show full text]